⦿ Type 1 and Type 2 Diabetes
⦿ Breast Cancer, Testicular Cancer, Prostate Cancer, Malignant Melanoma, Basal Cell Carcinoma
⦿ Coronary Artery Disease, Heart Attack, Hypercholesterolemia, Hypertension
⦿ Schizophrenia

Sometimes known as PGD, testing for all single-gene disorders when there is a family history.

⦿ Cystic Fibrosis
⦿ Thalassemia
⦿ Huntington's disease
⦿ Our test is universal, covering all known monogenic diseases.

Copies of previous genetic testing results are required. Saliva samples from other family members may be required. Our genetic counselor and laboratory director will review your case and determine if testing is possible.

‍

Rapid workups and broader accommodation of difficult cases means faster time to pregnancy for prospective patients.

‍

By combining linkage-based analysis of several hundred marker swith direct testing of the mutation, LifeView PGT-M provides the most convenient, cost effective, and accurate method available.

Sometimes known as chromosomal PGD, testing for translocations and inversions.

LifeView PGT-SR provides more than 5 times the resolution of NGS based testing and the ability to distinguish between balanced translocation carrier and truly normal embryos for our patients.

Previously known as PGS, testing to determine if the correct chromosome numberis in the embryo (explained here).

By combining copy number and genotyping data, LifeView provides the most accurate and highest resolution prediction of chromosomal abnormalities in the industry.  Fewer false positives means more embryos available for transfer.

Our position on the ethics, efficacy, and science of PGT-A:

‍

The LifeView laboratory process uses DNA samples from both parents(saliva) and the embryo (standard few-cell biopsy) to obtain a 99+percent accurate genotype. This accuracy has been carefully validated and has been published in peer reviewed scientific journals [1], and exceeds the adult accuracy given by common tests like 23andme.

‍

Using this genotype, future disease risks are predicted for each embryo, using methods validated to predict disease state in the adult. 

‍

This new technology, called polygenic risk prediction, uses AI applied to very large genomic datasets: genomes of up to a million individuals, together with their medical histories. There sulting polygenic risk scores (PRS) are tested in separate validation populations (i.e., people not used in the AI training) to ensure accuracy. This area of research is advancing rapidly, with hundreds of scientific papers published each year on polygenic risk prediction [2]. Widely validated risk predictors now exist for important conditions such as diabetes, heart disease, cancers, schizophrenia, and many more.

‍

The LifeView team are world leaders in this field [3]. In particular, they were the first to publish validation studies which showed that PRS could identify which sibling in a family was most likely to develop a specific disease condition later in life[4]. 

‍

Embryos are ranked in order of proposed transfer. Sibling selection using our ranking has been validated to reduce disease incidence. [5] Each disease incidence reduction is particular to that disease, to the ethnicity of the cohort, and the number of embryos. [6] The disease risk reduction is concurrent - which is to say that ranking the embryos based on a single, aggregate number (the Embryo Health Score) has been shown to reduce the diseases at the same time, in parallel.

Sometimes known as chromosomal PGD, testing for translocations and inversions. LifeView PGT-SR provides more than 5 times the resolution of older testing methods (NGS), and the ability to distinguish between balanced translocation carrier and truly normal embryos for our patients. When other labs using the older methods reject cases, they send them to us. Our accuracy exceeds 99%. [1]

Sometimes known as PGD, testing for single-gene disorders where there is a family history. An example of PGT-M is screening against Cystic Fibrosis.

‍

Combining linkage-based analysis of several hundred markers with direct testing of the mutation, LifeView provides the fastest, most cost effective, and accurate PGT-M method. Accuracy exceeds 99.9%. [1]

Previously known as PGS, testing to determine whether chromosome count is normal. By combining copy number and genotyping data, LifeView provides the most accurate, highest resolution prediction of chromosomal abnormalities in IVF than older testing methods (NGS).

‍

LifeView’s fewer false positives means more embryos available for transfer. LifeView’s fewer false negatives means embryos that are transferred will implant with higher likelihood, and miscarryless frequently. We have shown significantly better outcomes on these three metrics than other labs: less than half the normal miscarriage rate, and almost twice the normal pregnancy rate per cycle. [7]